Contents 2 min read
Claim and source comparison
Phenylpiracetam: a mouse behavioral experiment and the 2026 WADA List.
· Bounded source comparison; not a complete clinical review or independent medical endorsement.
Animal study
Zvejniece et al. (2011) compared R and S phenylpiracetam enantiomers in mice; memory responses differed by isomer. This preclinical trial does not establish 20–60-fold superiority to piracetam in humans or clinical benefits via DAT/NET.
The experiment compared R and S isomers in mice. It does not establish effective human doses, adverse-effect rates or tolerance duration.
Source 2 · Abstract read
Regulatory scientific assessment
WADA’s 2026 list prohibits fonturacetam [4-phenylpiracetam (carphedon)] in competition under S6.A stimulants. A prohibited-list entry is not evidence of clinical efficacy or safety in healthy people.
This classification concerns the 2026 competition rules. It does not establish clinical efficacy, safe use or medicine approval in other countries.
Source 3 · Official summary read
Correction · 2026-11-11. Sources were added for the mouse findings and WADA classification. Unsupported claims about clinical superiority, mechanisms and adverse-effect frequency were removed.
What is Phenylpiracetam?
Phenylpiracetam is a synthetic racetam. Stimulant and memory mechanisms have been studied in animals; cognitive superiority or a safe cycling regimen in healthy people has not been established.
Mechanism of Effect
Zvejniece et al. (2011) compared R and S phenylpiracetam enantiomers in mice; memory responses differed by isomer. This preclinical trial does not establish 20–60-fold superiority to piracetam in humans or clinical benefits via DAT/NET.
Clinical Evidence
The experiment compared R and S isomers in mice. It does not establish effective human doses, adverse-effect rates or tolerance duration.
WADA’s 2026 list prohibits fonturacetam [4-phenylpiracetam (carphedon)] in competition under S6.A stimulants. A prohibited-list entry is not evidence of clinical efficacy or safety in healthy people.
⚠ Tolerance and Limited Evidence Warning
There is insufficient clinical evidence that a particular break or cycling schedule prevents tolerance or improves efficacy and safety.
Dose information and research limits
This dose information describes research or product context; it is not a personal prescription, established safe upper limit or efficacy guarantee for healthy people. Extracts and different formulations should not be treated as equivalent milligram for milligram.
Safety and Side Effects
The animal experiment reviewed here does not establish human adverse-effect or interaction rates for phenylpiracetam. A validated personal dose or cycling protocol is unavailable.
Sources
- Malykh AG & Sadaie MR (2010). Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders. Drugs, 70(3), 287–312. PubMed · PMID 20166767
- Zvejniece L, et al. (2011). Investigation into stereoselective pharmacological activity of phenotropil. Basic & Clinical Pharmacology & Toxicology, 109(5), 407–412. PubMed · PMID 21689376
- World Anti-Doping Agency. The 2026 Prohibited List. https://www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf World Anti-Doping Agency
Link verification checks the identity of the publication; it does not constitute independent expert review of clinical claims. Our evidence and source methodology · Source directory
Frequently Asked Questions
Phenylpiracetam is a synthetic racetam. Stimulant and memory mechanisms have been studied in animals; cognitive superiority or a safe cycling regimen in healthy people has not been established.
There is insufficient clinical evidence that a particular break or cycling schedule prevents tolerance or improves efficacy and safety.
The animal experiment reviewed here does not establish human adverse-effect or interaction rates for phenylpiracetam. A validated personal dose or cycling protocol is unavailable.
Sale and import status in Türkiye must be checked for the specific product. Verify supplement approval in the Ministry of Agriculture and Forestry GGBS list, and medicine authorization and conditions of use in TİTCK records. Online availability does not establish approval or unrestricted personal import; current Ministry of Trade conditions apply to postal and express shipments.
No established timeframe